Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle

Ou, Xia; Guo, Lili; Wu, Jiang; Mi, Kai; Yin, Ning; Zhang, Guangming; Zhang, Dongliang; Sun, Maosheng

doi:10.4161/hv.23940

Cited by 16 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Below the age of 21 they should instead have been given the neonatal vaccination. Coverage of HBV vaccination has been estimated to be of 97% in Northern Italy, but only 60% in the South, with intermediate percentages in Central Italy [ 29 , 30 , 31 , 32 , 33 , 49 ]. The aim of this study is to estimate vaccinal protection against HBV infection in young DUs, using Anti-HBcAb as a marker of prior HBV infection.…”

Section: Methodsmentioning

confidence: 99%

“…In Italy, an HBV vaccination campaign for high-risk groups started in 1983. Despite the decreased circulation of HBV in the late 1980s, a compulsory universal vaccination against HBV was introduced for all newborns and for 12-year-old children (a double cohort policy of mandatory immunisation) in 1991, moving to compulsory vaccination of newborns only in 2003 [ 17 , 18 , 29 , 30 ]. In Italy, the prevalence of chronic HBV carriers decreased from 3% in 1980 to 0.9% in 1997 [ 17 , 29 , 30 , 31 ].…”

Section: Introductionmentioning

confidence: 99%

“…Substantial evidence suggests that after primary immunization with HBV vaccine, Anti-HBcAb levels decline slowly and 17%–50% of young adults vaccinated have low or undetectable concentrations of antibodies 10–15 years after vaccination, but even when protective antibody titre declines to <10 mIU/mL, nearly all vaccinated subjects are considered to remain protected against infection, probably through selective expansion of clones of antigen-specific B and T lymphocytes [ 17 , 29 , 30 , 31 , 32 ]. For these reasons most vaccinees retain immune memory and a lasting protection against HBV for up to two decades after completion of immunisation programs [ 17 , 29 , 30 , 33 , 34 ]. Evidence suggests that the immunological response in DUs is impaired compared to the general population.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Let It “B”? The Role of Hepatitis B Universal Vaccination among Italian Problematic Drug Users

Lugoboni

Pavarin²,

Resentera

et al. 2015

IJERPH

View full text Add to dashboard Cite

Hepatitis B virus (HBV) hepatitis is extremely common among problematic drug users (DUs). As of 2012, 47 of the 53 European countries had implemented a universal hepatitis B vaccination programme, a scenario that could radically change its spread. Even so, drug users are still one of the main groups at risk of being infected by HBV, exposing the fact that universal vaccination still has not managed to reach an optimal level of contagion protection. In order to evaluate the role of universal HBV vaccination in protecting against risk behaviour related to the use of illicit drugs, a group of 748 DUs, 511 male and 237 female, was tested for HBV markers, at their first access to public addiction clinics in the metropolitan area of Bologna, Italy. 487 were born after 1981, so they were eligible to have received HBV vaccination in adolescence or at birth; in these subjects antibodies against HBV core antigen had the significant prevalence of 6.2%. Universal HBV vaccination has shown evidence of protecting against infection in the general population. These results, amongst the first to evaluate actual protection in DUs vaccinated at birth or during adolescence, show that compulsory universal vaccination does not solve the problem of HBV transmission in the most at risk groups and that additional strategies must be studied and implemented to address this issue.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Let It “B”? The Role of Hepatitis B Universal Vaccination among Italian Problematic Drug Users

Lugoboni

Pavarin²,

Resentera

et al. 2015

IJERPH

View full text Add to dashboard Cite

show abstract

“…Ongoing phase II trials in patients with mild-to-moderate hypertension are exploring these issues. 122 Preclinical studies are evaluating in hypertensive rodent models the safety and efficacy of vaccines against various peptide sequences within the Ang II type 1 receptor, ATRQB-001 and ATR12181, 123,124 against Ang II conjugated via the N-terminus to keyhole limpet hemocyanin 125 and against a chimeric protein (pHAV-4 Ang IIs) that presents 4 successive repeated Ang II sequences as the functional epitope on the surface of the hepatitis A virus-like particle 126 ( Figure 2; Table). In all cases, significant BP reductions were achieved, keeping alive the concept that vaccine therapy might be useful in the treatment of human hypertension and its complications.…”

Section: Vaccinesmentioning

confidence: 99%

New Approaches in the Treatment of Hypertension

2015

View full text Add to dashboard Cite

Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and prevents cardiovascular disease outcomes. Despite a plethora of available treatment options, a substantial portion of the hypertensive population has uncontrolled blood pressure. The unmet need of controlling blood pressure in this population may be addressed, in part, by developing new drugs and devices/procedures to treat hypertension and its comorbidities. In this Compendium Review, we discuss new drugs and interventional treatments that are undergoing preclinical or clinical testing for hypertension treatment. New drug classes, eg, inhibitors of vasopeptidases, aldosterone synthase and soluble epoxide hydrolase, agonists of natriuretic peptide A and vasoactive intestinal peptide receptor 2, and a novel mineralocorticoid receptor antagonist are in phase II/III of development, while inhibitors of aminopeptidase A, dopamine β-hydroxylase, and the intestinal Na + /H + exchanger 3, agonists of components of the angiotensin-converting enzyme 2/angiotensin(1–7)/Mas receptor axis and vaccines directed toward angiotensin II and its type 1 receptor are in phase I or preclinical development. The two main interventional approaches, transcatheter renal denervation and baroreflex activation therapy, are used in clinical practice for severe treatment resistant hypertension in some countries. Renal denervation is also being evaluated for treatment of various comorbidities, eg, chronic heart failure, cardiac arrhythmias and chronic renal failure. Novel interventional approaches in early development include carotid body ablation and arteriovenous fistula placement. Importantly, none of these novel drug or device treatments has been shown to prevent cardiovascular disease outcomes or death in hypertensive patients.

show abstract

“…The vaccine was able to induce Ang II–specific IgG antibodies in vaccinated SHR, suggesting that pHAV-4AngIIs was able to break immunological tolerance. These antibodies could effectively neutralize serum Ang II, as seen by a significant reduction in Ang II levels up to 87 pg/mL and a significant decrease in SBP and DBP up to –23/–12 mmHg [ 25 ].…”

Section: Targeted Antigens: Biological Markers In Hypertensionmentioning

confidence: 99%

Vaccines against components of the renin–angiotensin system

et al. 2020

View full text Add to dashboard Cite

Even though effective drugs for treating hypertension are available, a great percentage of patients have inadequate control of their blood pressure. Unwanted side effects and inappropriate oral drug adherence are important factors that contribute to the global problem of uncontrolled hypertension. Vaccination could provide a revolutionary therapy with long-lasting effects, increasing patient compliance and therefore better control of high blood pressure. Nowadays, current immunization approaches against hypertension target renin, angiotensin I, angiotensin II, and angiotensin II type 1 receptor, key elements of the renin-angiotensin system. This article reviews the different vaccination attempts with proteins and peptides against the different molecules of the renin-angiotensin system in the last two decades, safety issues, and other novel prospects biomarkers in hypertension, and summarizes the potential of this immunomodulatory approach in clinical practice.

show abstract

Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle

Cited by 16 publications

References 18 publications

Let It “B”? The Role of Hepatitis B Universal Vaccination among Italian Problematic Drug Users

Let It “B”? The Role of Hepatitis B Universal Vaccination among Italian Problematic Drug Users

New Approaches in the Treatment of Hypertension

Vaccines against components of the renin–angiotensin system

Contact Info

Product

Resources

About